Physician profile
Yufeng Zhang
NPI 1619079142
$2,665.13
in general payments reported to CMS, 2019-2025
20 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $157 · 2021: $321 · 2022: $281 · 2023: $735 · 2024: $448 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $629.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $496.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $366.43 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $213.21 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $145.31 | 2023 | Watchman |
| Actelion Pharmaceuticals US, INC. | $124.91 | 2023 | Uptravi, Opsumit |
| Amgen INC. | $123.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.71 | 2019-2024 | Jardiance |
| Abbott Laboratories | $66.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.71 | 2021-2023 | Verquvo |
| Heartflow, INC. | $60.94 | 2022-2023 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $54.58 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $47.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $38.48 | 2019-2022 | |
| Bridgebio Pharma, INC. | $31.69 | 2025 | Attruby |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $23.60 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $19.68 | 2021 | |
| Novo Nordisk INC | $17.70 | 2024 | Wegovy |
| Lundbeck LLC | $16.83 | 2019 | |
| Infobionic, INC | $15.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yufeng Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.